-+ 0.00%
-+ 0.00%
-+ 0.00%

Cuprina Holdings Signs Joint Venture Agreement With Aiodine Laboratory To Develop, Test Iodine-Based Disinfectant Solution To Treat Chronic And Acute Wounds

Benzinga·11/18/2025 13:32:18
Listen to the news

Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today said it has signed a joint venture (JV) company agreement with Singapore-based Aiodine Laboratory Pte Ltd. ("Aiodine") to develop, test and market that company's novel iodine-based disinfectant solution as a treatment for chronic and acute wounds, and in other common antiseptic applications.

Initial applications for this iodine-based solution will focus on an antiseptic wound care formulation, disinfectants, and daily home-use antiseptics, with additional opportunities under evaluation in personal care, oral hygiene and veterinary applications. The companies plan to commence the clinical studies required to achieve regulatory approvals for these applications in 2026.

According to the JV company agreement, Cuprina shall be responsible for implementing global sales strategies, marketing campaigns, and distribution networks for licensed products. Aiodine Laboratory shall be responsible for providing the JV with its proprietary iodine technology and technical expertise.